Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Amundi in connection with the acquisition of Lyxor Asset Management from Société Générale for EUR 825 million
Mandate

Vinge advises Amundi in connection with the acquisition of Lyxor Asset Management from Société Générale for EUR 825 million

September 08, 2021 Employment and Benefits Banking and Finance Corporate Tax

Vinge has advised Amundi, a division of the Crédit Agricole group, in connection with its acquisition of Lyxor from Société Générale.

Lyxor is a pioneer within, and the third largest actor in Europe with regard to exchange‑traded funds (ETFs), and via this acquisition Amundi will thereby strengthen its position as the European lead actor in the fast‑growing market for ETFs. The transaction is subject to customary approvals by public authorities and is expected to be completed not later than February 2022.

Vinge’s team consisted of responsible partner Fredrik Wilkens (Project Manager), Henrik Schön, Anton Sjökvist (Fund Issues), Åsa Gotthardson, Sara Strandberg and Ebba Svenburg (Employment Law), Maria Schultzberg, Henrik Wastenson and Karolin Ekström (Tax) as well as Ulf Nilsson (VAT).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025